The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications

Bibliography

• NISHIKAWA T, EDELSTEIN D, BROWNLEE M: The missing link: a single unifying mechanism for diabetic complications. Kidney Int. (2000) 58\(Suppl. 77):S26–S30.
   Google Scholar
• ART WOHL M, RODEN M, WALDHAUSL W, A, BAUMGARTNER-PARZER SM: Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J. (2004) 18:146–148.
   PubMed Web of Science ®Google Scholar
• VIRAG L, SZABO C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. PharmacoL Rev. (2002) 54:375–429.
   PubMed Web of Science ®Google Scholar
• AIELLO L, BURSELL S-E, DEVRIES T et al.: Protein kinase C B inhibitor Ly333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes (1999) 48\(Suppl. 2):A19.
   Google Scholar
• VINIK A, BRIL V KEMPLER P et al.: Treatment of symptomatic diabetic peripheral neuropathy with protein kinase inhibitor ruboxistaurin mesylate during a 1-year randomized, placebo-controlled, double-blind clinical trial. Clin. Ther. (2005) 27:1164-1180. first reported Phase II trial of 1213X in diabetic neuropathy.
   Google Scholar
• AIELLO L, BURSELL S, CLERMONT A et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective B-isoform-selective inhibitor. Diabetes (1997) 46:1473–1480.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N EngL J. Med. (1994) 331:1480–1487.
   PubMed Web of Science ®Google Scholar
• ISHII H, JIROUSEK MR, KOYA D et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-13 inhibitor. Science (1996) 272:728–731.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, COTTER Mk LOW PA: Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am. J. PhysioL (1991) 261:E1–E8.
   PubMed Web of Science ®Google Scholar
• NAKAMURA J, KATO K, HAMADA Y et al.: A protein kinase C-B-selective inhibitor ameliorates neural dysfunction in-induced diabetic rats. Diabetes (1999) 48:2090–2095.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, COTTER Mk HORROBIN DH, TRITSCHLER HJ: Effects of a-lipoic acid on neurovascular fitnction in diabetic rats: interaction with essential fatty acids. Diabetologia (1998) 41:390–399.
   PubMed Web of Science ®Google Scholar
• YOKOTA T, MARC, PARK JY et ed.: Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes (2003) 52:838–845.
   Google Scholar
• ABIKO T, ABIKO k CLERMONT AC et al.: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 52:829–837.
   Google Scholar
• KOWLURU R, JIROUSEK M, L, ENGERMAN RL, KERN T: Diabetes-induced disorders of retinal protein kinase C and Na,K-ATPase are inhibited by ruboxistaurin. Diabetes (1996) 45:16A (Abstract).
   Google Scholar
• NONAKA A, KIRYU J, TSUJIKAWA A et al.: PKC-13 inhibitor (LY333531) attenuates leukocyte entrapment in retinal of diabetic rats. Invest. OphthalmoL Vis. Sci. (2000) 41:2702–2706.
   PubMed Web of Science ®Google Scholar
• KOWLURU RA: Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. (2001) 38:179–185.
   PubMed Web of Science ®Google Scholar
• IDO Y, CHANG KC, LEJEUNE WS et al.: Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcircu/ation (2001) 8:251–263.
   PubMed Web of Science ®Google Scholar
• KITADA M, KOYA D, SUGIMOTO T et al.: Translocation of glomerular p47phox and p67phox by protein kinase C-0 activation is required for oxidative stress in diabetic nephropathy. Diabetes (2003) 52:2603–2614.
   PubMed Web of Science ®Google Scholar
• MAZZI P, DONINI M, MARGOTTO D, WIENTJES F, DUST S: IFN-y induces gp9lphox expression in human monocytes via protein kinase C-dependent phosphorylation of PU.1. J. ImmunoL (2004) 172:4941–4947.
   Google Scholar
• KUBOKI K, JIANG ZY, N et al.: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation (2000) 101:676–681.
   PubMed Web of Science ®Google Scholar
• BOHLEN HG: Protein kinase pH in Zucker obese rats compromises oxygen and flow-mediated regulation of nitric oxide formation. Am. J. Physiol. Heart. PhysioL (2004) 286:H492–H497.
   PubMed Web of Science ®Google Scholar
• CAMERON N, COTTER M: Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes (1997) 46(2):531–S37.
   Google Scholar
• •Overview of the pathogenetic mechanism of diabetic neuropathies.
   Google Scholar
• WAYS DK, SHEETZ MJ: The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm. (2000) 60:149–193.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, EATON SEM, COTTER MA, TESFAYE S: Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia (2001) 44:1973–1988.
   PubMed Web of Science ®Google Scholar
• OZAKI H, YASUDA K, KIM YS et al.: role of the protein kinase C/CPI-17 pathway in the augmented contraction of human myometrium after gestation. Br. J. PharmacoL (2003) 140:1303–1312.
   PubMed Web of Science ®Google Scholar
• AREZZO JC: New developments in the diagnosis of diabetic neuropathy. Am. J. Med. (1999) 107:9S–16S.
   Google Scholar
• HOTTA N, KAKUTA H, FUKASAWA H et al.: Effect of niceritol on streptozocin-induced diabetic neuropathy in rats. Diabetes (1992) 41:587–591.
   PubMed Web of Science ®Google Scholar
• CAMERON NE. COTTER Mk Effects ofprotein kinase CB inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab. Res. Rev. (2002) 18(4):315–323.
   PubMed Web of Science ®Google Scholar
• KIM H, SASAKI T, MAEDA K, KOYA D, KASHIWAGI A, YASUDA H: Protein kinase CB selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes (2003) 52:2102–2109.
   PubMed Web of Science ®Google Scholar
• •Animals study showing the effects on nerve function.
   Google Scholar
• DYCK PJ, KRATZ KM, KARNES JL et al.:The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology (1993) 43:817–824.
   PubMed Web of Science ®Google Scholar
• VINIK A. MEHRABYAN A: Diabetic neuropathies. Med. Clin. North Am. (2004) 88(4):947–999.
   PubMed Web of Science ®Google Scholar
• •One of the most comprehensive reviews of diabetic neuropathy.
   Google Scholar
• BOULTON A. MALIK T, AREZZO JC, SOSENKO J: Diabetic somatic neuropathies: technical review. Diabetes Care (2004) 27:1458–1486.
   PubMed Web of Science ®Google Scholar
• MANES C, PAPAZOGLOU N, E et al.: Prevalence of diabetic neuropathy and foot ulceration: identification of potential risk factors-a population-based study. Wounds (2002) 14:11–15.
   Web of Science ®Google Scholar
• VINIK AT, MITCHELL BD, SB et al.: Epidemiology of the complications of diabetes. In: Diabetes: clinical science in practice. Robbins DC (Ed), Cambridge University Press, Cambridge, UK (1994):221–287.
   Google Scholar
• REIBER GE, PECORARO RE, KOEPSELL TD: Risk factors for amputation in patients with diabetes mellitus. A case- control study. Ann. Intern. Med (1992) 117:97–105.
   PubMed Web of Science ®Google Scholar
• ADLER Al, BOYKO EJ, AHRONI JH, SMITH DG: Lower-extremity amputation diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care (1999) 22:1029–1035.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• THE DCCT RESEARCH GROUP: Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes (1988) 37:476–481.
   Google Scholar
• THE DCCT RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N EngL J. Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• DYCK PJ, DAVIES JL, WILSON DM et al.: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care (1999) 22:1479–1486.
   PubMed Web of Science ®Google Scholar
• DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia (1998) 41:416–423.
   PubMed Web of Science ®Google Scholar
• GAEDE P, VEDEL P, LARSEN N, JENSEN G, PARVING H, 0: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N EngL J. Med. (2003) 348(5):383–393.
   PubMed Web of Science ®Google Scholar
• ••The demonstration that familypractitioners can reduce the neuropathic complications of diabetes.
   Google Scholar
• BOULTON AJ, VINIK A, AREZZO J et al. AND AMERICAN DIABETES ASSOCIATION: Position statement: iabetes neuropathies. Diabetes Care (2005) 28(4):956–962.
   PubMed Web of Science ®Google Scholar
• ••The first ever position statement ondiabetic neuropathy by the ADA.
   Google Scholar
• SIMA AA, LAUDADIO C: Design of controlled clinical trials for diabetic polyneuropathy. Semin. NeuroL (1996) 16:187–191.
   PubMed Web of Science ®Google Scholar
• ALBERS JW, BROWN MB, SIMA AA, GREENE DA: Nerve conduction measures mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology (1996) 46:85–91.
   Google Scholar
• SUNDKVIST G, ARMSTRONG FM, BRADBURY JE et al.: Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J. Diabetes Complications (1992) 6:123–130.
   PubMedGoogle Scholar
• CONSENSUS STATE: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care (1998) 11:592–597.
   Google Scholar
• VINIK AI, SUWANWALAIKORN S, STANSBERRY KB, HOLLAND MT, McNITT PM, COLEN LE: Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve (1995) 18:574–584.
   PubMed Web of Science ®Google Scholar
• DYCK PJ, BUSHEK W, SPRING EM et al.: Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care (1987) 10:432–440.
   PubMed Web of Science ®Google Scholar
• MALIK RA, NEWRICK PG, SHARMA AK, JENNINGS A, AH-SEE AK, MAYHEW TM: Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia (1989) 32:92–102.
   PubMed Web of Science ®Google Scholar
• GIANNINI C, DYCK P: Basement membrane reduplication and pericyte degernation precede development of diabetic polyneuropathy and are associated with its severity. Ann. NeuroL (1995) 37:498–504.
   PubMed Web of Science ®Google Scholar
• IZZO KL, SOBEL E, BERNEY S, DEMOPOULOS JT: Distal sensory nerves of the lower extremity in peripheral neuropathy: comparison of medial dorsal cutaneous and sural nerve abnormalities. Arch. Phys. Med. RehabiL (1985) 66:7–10.
   PubMed Web of Science ®Google Scholar
• IZZO KL, SOBEL E, DEMOPOULOS JT: Diabetic neuropathy: electrophysiologic abnormalities of distal lower extremity sensory nerves. Arch. Phys. Med. RehabiL (1986) 67:7–11.
   PubMed Web of Science ®Google Scholar
• KILLIAN JM, FOREMAN PJ: Clinical utility of dorsal sural nerve conduction studies. Muscle Nerve (2001) 24:817–820.
   PubMed Web of Science ®Google Scholar
• SHIN JB, SEONG YJ, LEE HJ, KIM SH, SUK H, LEE YJ: The usefulness of minimal F-wave latency and sural/radial amplitude ratio in diabetic polyneuropathy. Med. J. (2000) 41:393–397.
   Google Scholar
• BEHSE F, BUCHTHAL: Sensory action potentials and biopsy of the sural nerve in neuropathy. Brain (1978) 101:473–493.
   PubMed Web of Science ®Google Scholar
• VINIK A, TESFAYE S, ZHANG D, BASTYR E: LY333531 Treatment improves diabetic peripheral neuropathy (dpn) with symptoms. Diabetes (2002) 51\(Suppl. 2):A79.
   Google Scholar
• VINIK E, HAYES R, OGLESBY A et ell.: The development and validation of the Norfolk QOL-DN a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. TechnoL Ther. (2005) 7(3):497–508.
   Google Scholar
• •The only quality of life tool that was validated for clinical studies of diabetic neuropathy.
   Google Scholar
• APFEL SC, ASBURY A, BRIL Vet al.: Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. NeuroL Sci. (2001) 189:3-5 (Abstract).
   Google Scholar
• TESFAYE S: Symptomatic diabetic peripheral neuropathy (SDPN) treatment with the PKC B inhibitor ruboxistaurin: trial design. Diabetologia (2005) 48:A353.
   Web of Science ®Google Scholar
• KOYA D, JIROUSEK MR, UN YW, ISHII H, KUBOKI K, KING GL: Characterization of protein kinase CI3 isoform activation on the gene expression of transforming growth factor-I3, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. (1997) 100:115–126.
   PubMed Web of Science ®Google Scholar
• AUBERT R, HERZOG J, CAMUS MC, GUENET JL, LEMONNIER D: Description of a new model of genetic obesity: the dbPas mouse. J. Nutr. (1985) 115:327–333.
   PubMed Web of Science ®Google Scholar
• KOYA D, HANEDA M, NAKAGAWA H: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC B inhibitor in diabetic db/db mice, a rodent model for Type 2 diabetes. FASEB J. (2000) 114:439–447.
   Google Scholar
• KELLY DJ, ZHANG Y, HEPPER C et al.:Protein kinase CI3 inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes (2003) 52:512–518.
   PubMed Web of Science ®Google Scholar
• YASUDA Y, NAKAMURA J, HAMADA Y et al.: Role of PKC and TGF-I3 receptor in-induced proliferation of smooth muscle cells. Biochem. Biophys.. Commun. (2001) 281:71–77.
   PubMed Web of Science ®Google Scholar
• WAKASAKI H, KOYA D, SCHOEN FJ et al.: Targeted overexpression of protein kinase CI32 isoform in myocardium causes cardiomyopathy. Proc. NatL Acad. Sci. USA (1997) 94:9320–9325.
   PubMed Web of Science ®Google Scholar
• KELLY DJ, CHANTY A, GOW RM, ZHANG Y, GILBERT RE: Protein kinase CI3 inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J. Am. Soc. NephroL (2005) 16:1654–1660.
   PubMed Web of Science ®Google Scholar
• TRACHTMAN H, FUTTERWEIT S, CRIMMINS DL: High glucose inhibits nitric oxide production in cultured rat mesangial cells./ Am. Soc. NephroL (1997) 8:1276–1282.
   PubMed Web of Science ®Google Scholar
• BECKMAN J, GOLDFINE A, GORDON M, GARRETT L, CREAGER M: Inhibiton of protein kinase CB prevents Impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res. (2002) 90:107–111.
   PubMed Web of Science ®Google Scholar
• WAY KJ, ISSHIKI K, SUZUMA K et al.:Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase CI32 activation and diabetes. Diabetes (2002) 51:2709–2718.
   PubMed Web of Science ®Google Scholar
• GURUSAMY N, WATANABE K, MA M et al.: Inactivation of 14-3-3 protein exacerbates cardiac hypertrophy and fibrosis through enhanced expression of protein kinase CI32 in experimental diabetes. Biol. Pharm. Bull. (2005) 28:957–962.
   PubMed Web of Science ®Google Scholar
• BOYLE AJ, KELLY DJ, ZHANG Y et al.: Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J. MoL Cell CardioL (2005) 39:213–221.
   PubMed Web of Science ®Google Scholar
• TUTTLE KR, BAKRIS GL, TOTO RD, McGILL J, HU K, ANDERSON P: Effect of ruboxistaurin on albuminuria and GFR in persons with Type 2 diabetes and nephropathy. Diabetes (2005) 28(11):2686–2690.
   Web of Science ®Google Scholar
• ••The first paper to demostrate theeffectiveness of Rl3X in diabetic nephropathy.
   Google Scholar
• KEMPEN JH, O'COLMAIN BJ, LESKE MC et al.: The prevalence of diabetic retinopathy among adults in the United States. Arch. OphthalmoL (2004) 122:552–563.
   Google Scholar
• KLEIN R, KLEIN BE, MOSS SE: The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab. Rev. (1989) 5:559–570.
   PubMed Web of Science ®Google Scholar
• THE DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL: Blindness caused by diabetes-Massachusetts. MMWR Morb. Mortal. Wkly Rep. (1996) 45:937-941 (Abstract).
   Google Scholar
• SUZUMA K, TAKAHARA N, SUZUMA I et al.: Characterization of protein kinase CB isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. NatL Acad. Sci. USA (2002) 99:721–726.
   PubMed Web of Science ®Google Scholar
• FUNATSU H, YAIVIASHITA H, IKEDA T, NAKANISHI Y, KITANO S, HORT S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am. J. OphthalmoL (2002) 133:537–543.
   PubMed Web of Science ®Google Scholar
• XU X, ZHU Q, XIA X, ZHANG S, GU Q,LUO D: Blood-retinal barrier breakdown by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr. Eye Res. (2004) 28:251–256.
   PubMed Web of Science ®Google Scholar
• DANIS RP, BINGAMAN DP, JIROUSEK M, YANG Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCI3 inhibition with LY333531. Invest OphthalmoL Vis. Sci. (1998) 39:171–179.
   PubMed Web of Science ®Google Scholar
• AIELLO L, BURSELL S, DEVRIES T, ALATORRE C, KING G, WAYS D: Amelioration of abnormal retinal hemodynamics by a protein kinase CB selective inhibitor (LY333531) in patients with diabetes: results of Phase I safety and pharmacodynamic clinical trial.. OphthalmoL Vis. SGT. (1999) 40:S192 (Abstract).
   Google Scholar
• AIELLO L, CLERMONT A. ARORA V, DAVIS M, SHEETZ M, BURSELL S-E: Inhibition of PKC B by oral administration of ruboxistaurin (LY333531) mesylate is well-tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. OphthalmoL Vis. Sci. (2005) (In Press) (Abstract).
   Google Scholar
• THE PKC-DRs STUDY GROUP: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproflierative diabetic retinopathy. Diabetes (2005) 54(7):2188–2197.
   PubMed Web of Science ®Google Scholar
• •The clear demonstration of reduced macular oedema and slowing of progression of retinopathy.
   Google Scholar
• CAMPOCHIARO PA: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. OphthalmoL Vis. Sci. (2004) 45:922–931.
   PubMed Web of Science ®Google Scholar
• AIELLO L: The effect of the PKC inhibitorruboxistaurin on moderate visual loss: the PKC-DRS2 trial baseline characteristics and preliminary results. American Academy of Ophthalmology Annual Meeting, Chicago, USA (2005) (Abstract).
   Google Scholar